India upholds Nexavar compulsory license, Bayer vows to fight on
This article was originally published in Scrip
Executive Summary
India's Intellectual Property Appellate Board (IPAB) has dismissed Bayer's appeal in a crucial case concerning the compulsory license (CL) granted for its anticancer Nexavar (sorafenib tosylate) to the domestic firm, Natco Pharma, in 2012.